IDH1 and acute myeloid leukemia: In molecularly defined high-risk relapsed or refractory AML patients, Ivosidenib (IDH1 inhibitor) monotherapy exhibited a lower incidence of grade 3 or higher treatment-related adverse events compared to previous outcomes, and induced deep and durable remissions, leading to favorable clinical outcomes (30).